Discovery & history

• How liraglutide bridged twice-daily exenatide and weekly semaglutide
• Why a fatty-acid tail and albumin binding make it once-daily
• What the LEAD, SCALE, and LEADER trials actually showed
• How to read its approved dosing, safety warnings, and place in 2026

1. 01 Discovery & history The molecule that made GLP-1 therapy a once-daily habit free
2. 02 Molecular design & pharmacokinetics How a fatty-acid tail turns two minutes into thirteen hours paid
3. 03 GLP-1 receptor mechanism & incretin biology One receptor, many organs, one coordinated signal paid
4. 04 Type 2 diabetes evidence: the LEAD program Six trials that made liraglutide a diabetes standard paid
5. 05 Obesity evidence: the SCALE program A second approval, at a higher dose paid
6. 06 Cardiovascular & kidney outcomes: LEADER When a diabetes drug started preventing cardiovascular events paid
7. 07 Other applications: pediatric, liver, and sleep Beyond adult diabetes and obesity paid
8. 08 In context: newer agents & regulatory status The bridge molecule in a weekly-dosing world paid
9. 09 Dosing & Administration The approved titration, and why it is deliberately slow paid
10. 10 Safety & side effects A well-characterized profile, with real warnings paid
11. 11 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

Liraglutide sits in the middle of a fast-moving lineage. The earlier GLP-1 drug exenatide needed twice-daily shots, and it is the comparator liraglutide was tested against head to head in LEAD-6. Liraglutide, a fully human GLP-1 analog engineered for once-daily use, arrived in 2010, and within a decade weekly semaglutide pushed past it on convenience and weight loss. The timeline marks the beats.

Read the timeline as a bridge rather than a peak. Liraglutide proved that a daily GLP-1 injection could work, that a GLP-1 drug could lower cardiovascular risk, and that it could be approved for obesity, and the newer agents inherited that clinical and regulatory groundwork.

Strip away the branding and liraglutide is the human GLP-1 peptide with two small tweaks. The Victoza label describes it as 97% homologous to native human GLP-1, with arginine substituted for lysine at position 34 and a C-16 fatty acid attached through a glutamic-acid spacer at the remaining lysine, position 26. The backbone is the natural hormone, so it hits the same receptor. The derivation view shows the human sequence and the fragment liraglutide keeps; the numbers card summarizes what those tweaks buy you.

The single lysine-to-arginine swap is not cosmetic: it clears the way so the fatty acid attaches at exactly one site. That precision is why liraglutide behaves predictably rather than as a messy mixture. Everything downstream, from the 13-hour half-life to the daily pen, flows from those two deliberate edits to a natural hormone.

Liraglutide is one member of a crowded family, and the differences are practical: how often you inject and how much weight tends to come off. Tap each drug to compare dosing rhythm and what the trials behind this course actually measured. Only two of those comparisons are randomized head-to-head results: LEAD-6 against exenatide in diabetes, and STEP 8 against semaglutide at the weight dose.

Keeping this map in mind prevents a common error: judging liraglutide by present-day expectations shaped by semaglutide marketing. In its own era it was a leap forward, and it still holds specific advantages, like fine dose adjustment and a much shorter half-life, that this course will return to.

Liraglutide is unusual among peptides taught here because its evidence is genuinely strong: multiple randomized trials and a hard cardiovascular outcomes study. So the honest ceiling looks different. The task is not to question whether it works, but to keep its proven uses separate from its weaker or extrapolated ones, and to remember that its weight-loss magnitude is real but modest next to newer drugs.

A handful of claims dominate the online conversation about liraglutide. Held against the trial evidence, most are broadly true but need a qualifier: the effect is real, yet smaller or narrower than the headline suggests. Tap each claim to see the honest verdict and its evidence tier, and notice how often the fix is a number rather than a flat yes or no.

The recurring theme is proportion, not truth. Liraglutide genuinely does these things; the distortion is one of size and certainty. Learning to attach the right qualifier to a real effect is the core literacy skill this course builds, and it matters most for an approved drug people actually take.

Most new GLP-1 prescriptions now go to weekly agents, yet liraglutide has not vanished. It occupies specific niches where daily dosing, a long record, or generic pricing matter more than raw magnitude. The two panels lay out where it still makes sense against where a newer drug is usually the better call.

The lesson is that "older" is not the same as "obsolete." Liraglutide is displaced for the average case but preferable in several concrete ones, and knowing which is which is exactly the kind of judgment this course is designed to give you.